Bicycle Therapeutics plc — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; the filing is an annual report, not a standalone fourth-quarter report. Bicycle is a clinical-stage biotechnology company developing synthetic bicyclic peptide medicines. It has no approved products and generated no product-sales revenue; reported revenue is from collaborations.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | FY2022 | FY2021 |
|---|---|---|
| Collaboration revenue | $14.5 | $11.7 |
| Research and development expense | $81.6 | $44.9 |
| General and administrative expense | $49.5 | $32.4 |
| Operating loss | $(116.7) | $(65.6) |
| Net loss | $(112.7) | $(66.8) |
| Net loss per ordinary share, basic and diluted | $(3.80) | $(2.67) |
| Net cash used in operating activities | $(86.1) | $(14.8) |
| Cash used in investing activities | $(19.0) | $(2.0) |
| Cash and cash equivalents at year-end | $339.2 | $438.7 |
FY2022 total operating expenses were $131.1 million, against collaboration revenue of $14.5 million. The filing does not present a meaningful product gross margin; the company has no product sales. Collaboration revenue mainly came from Ionis ($9.3 million), Genentech ($3.6 million), AstraZeneca ($1.2 million) and the Dementia Discovery Fund ($0.4 million).
At December 31, 2022, total assets were $410.6 million, total liabilities $139.8 million and shareholders’ equity $270.8 million. Hercules loan principal was $30.0 million (balance-sheet carrying value $30.3 million); the stated interest rate was 9.05%. Up to $45.0 million of additional borrowing was available subject to conditions. The loan’s interest-only period runs to April 1, 2025, with maturity extended to July 1, 2025. Management said existing cash should fund operating expenses and capital requirements for at least 12 months from the filing date, while warning that estimates depend on assumptions and additional funding will be needed.
Changes versus FY2021
- Net loss increased by $45.9 million as operating expenses rose substantially; R&D increased $36.7 million and G&A increased $17.1 million. Higher clinical-program spending, headcount, share-based compensation and facilities costs contributed.
- Collaboration revenue rose $2.8 million, primarily from Ionis, partly offset by lower Genentech revenue.
- Operating cash use increased $71.3 million. The company cited higher losses and working-capital movements, including lower deferred-revenue cash inflows than in 2021.
- Investing cash use increased with laboratory equipment and leasehold improvements. FY2022 financing cash inflow was $6.7 million, versus $320.7 million in FY2021, which included a follow-on offering and larger ATM sales.
Business, outlook and material items
- Pipeline: BT5528 (EphA2), BT8009 (Nectin-4) and BT7480 (Nectin-4/CD137) were in company-sponsored Phase I/II trials. BT1718 (MT1-MMP) was in a Cancer Research UK-sponsored Phase I/IIa trial; BT7455 remained preclinical with IND-enabling work underway.
- BT5528: FY2022 dose-escalation results included tumor responses in small EphA2-positive patient subsets: among nine evaluable ovarian patients, one complete and one partial response were reported (22% overall response rate); among three evaluable urothelial patients, two partial responses were reported. Expansion-cohort enrollment was ongoing. These are early, limited-patient findings, not confirmatory efficacy evidence.
- BT8009: The Phase I dose escalation was completed and Phase II expansion began in November 2022. In January 2023, after year-end, FDA granted Fast Track designation for previously treated locally advanced or metastatic urothelial cancer; additional Phase I results were presented in February 2023.
- Outlook: Management expects continued operating losses and materially higher spending as clinical programs advance. The filing provides no financial revenue, earnings or cash-flow guidance. Development, regulatory approval, commercialization and profitability remain uncertain.
- Funding and contingencies: The company relies on collaborations, equity financing and debt, and may need further capital. Potential future milestone payments include up to $92.4 million under the Pepscan settlement/license agreement and aggregate Cancer Research UK milestones disclosed for BT1718 and BT7401; these are contingent on future events, not stated as currently due. The company reported no material legal proceedings.
- Other risks: Clinical-trial uncertainty, possible adverse effects, patient enrollment, reliance on contract manufacturers and collaborators, competition, intellectual-property protection, reimbursement and pricing, foreign exchange, data security, and macroeconomic and geopolitical conditions are significant risks. The auditor gave an unmodified opinion on the financial statements and identified Genentech expansion-option revenue accounting as a critical audit matter. Management concluded financial-reporting controls were effective; the auditor did not provide an internal-control attestation.
Investor verification checklist
- Track cash burn, collaboration receipts and deferred revenue, and test the stated cash runway against trial and facility spending.
- Review forthcoming clinical data for BT5528, BT8009 and BT7480, including sample sizes, biomarker selection, durability, safety and dose rationale.
- Confirm the status and terms of Hercules borrowing, including interest, maturity, covenants and conditions on the undrawn facility.
- Assess whether collaboration programs advance and whether milestone, option or research payments recur; FY2022 revenue is not product revenue.
- Review contingent obligations, especially Pepscan and Cancer Research UK milestones, and any change in the company’s rights to BT1718 or BT7401 data and development.